Literature DB >> 24712891

Considerations in individualizing prophylaxis in patients with haemophilia A.

L A Valentino1.   

Abstract

Prophylaxis is considered optimal care for children and adults with severe haemophilia A because of its proven ability to reduce joint and other bleeding episodes. However, a 'one size fits all' approach to prophylaxis is not ideal, potentially leading to over-treatment in some individuals and under-treatment in others. Moreover, a generic plan fails to take into account a patient's lifestyle and personal preferences. This article reviews the factors contributing to bleeding risk and joint damage and uses case studies to illustrate how these contributors can be weighed to individualize the prophylactic regimen, thereby increasing the likelihood of therapeutic success.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  FVIII; haemophilia; individualizing; personalizing; prophylaxis

Mesh:

Substances:

Year:  2014        PMID: 24712891     DOI: 10.1111/hae.12438

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

Review 1.  Treatment Options in Hemophilia.

Authors:  Wolfgang Miesbach; Joachim Schwäble; Markus M Müller; Erhard Seifried
Journal:  Dtsch Arztebl Int       Date:  2019-11-22       Impact factor: 5.594

2.  Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973).

Authors:  Paolo Angelo Cortesi; Giovanni Di Minno; Ezio Zanon; Gaetano Giuffrida; Rita Carlotta Santoro; Renato Marino; Lucia Sara D'Angiolella; Ippazio Cosimo Antonazzo; Ginevra Squassabia; Francesco Clemente; Danilo Di Laura; Ernesto Cimino; Samantha Pasca; Daniela Nicolosi; Lorenzo Giovanni Mantovani
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

Review 3.  Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology.

Authors:  Ionut Hotea; Melen Brinza; Cristina Blag; Alina-Andreea Zimta; Noemi Dirzu; Corina Burzo; Ioana Rus; Dragos Apostu; Horea Benea; Mirela Marian; Alexandru Mester; Sergiu Pasca; Sabina Iluta; Patric Teodorescu; Ciprian Jitaru; Mihnea Zdrenghea; Anca Bojan; Tunde Torok-Vistai; Radu Niculescu; Cristina Tarniceriu; Delia Dima; Cristina Truica; Margit Serban; Ciprian Tomuleasa; Daniel Coriu
Journal:  Ann Transl Med       Date:  2021-07

Review 4.  Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.

Authors:  Pratima Chowdary
Journal:  Int J Hematol       Date:  2018-10-09       Impact factor: 2.490

5.  Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.

Authors:  Anita Shah; Alexander Solms; Dirk Garmann; Yvonne Katterle; Verzhiniya Avramova; Stanislav Simeonov; Toshko Lissitchkov
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

Review 6.  Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.

Authors:  Pratima Chowdary
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

7.  Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program.

Authors:  Samuel Sarmiento Doncel; Gina Alejandra Diaz Mosquera; Javier Mauricio Cortes; Nelson Ramirez Plazas; Francisco Javier Meza; Carol Agudelo Rico
Journal:  Hematol Rep       Date:  2021-11-26

8.  Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).

Authors:  Claudia Djambas Khayat; Genadi Iosava; Irina Romashevskaya; Oleksandra Stasyshyn; Marta Julia Lopez; Maria Teresa Pompa; Tobias Rogosch; Wilfried Seifert
Journal:  J Blood Med       Date:  2021-06-21

Review 9.  Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A.

Authors:  Pratima Chowdary; Emma Fosbury; Anne Riddell; Mary Mathias
Journal:  J Blood Med       Date:  2016-09-12

10.  Global coagulation assays in hemophilia A: A comparison to conventional assays.

Authors:  Saman Aghighi; Anne Riddell; Christine A Lee; Simon A Brown; Edward Tuddenham; Pratima Chowdary
Journal:  Res Pract Thromb Haemost       Date:  2019-12-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.